WO2026026952 - AGT-TARGETING DOUBLE-STRANDED SIRNA, CONJUGATE THEREOF, AND USE THEREOF
National phase entry is expected:
Publication Number
WO/2026/026952
Publication Date
05.02.2026
International Application No.
PCT/CN2025/112133
International Filing Date
01.08.2025
Title **
[English]
AGT-TARGETING DOUBLE-STRANDED SIRNA, CONJUGATE THEREOF, AND USE THEREOF
[French]
NOUVEL ARNSI DOUBLE BRIN CIBLANT AGT, CONJUGUÉ ASSOCIÉ ET UTILISATION ASSOCIÉE
[Chinese]
一种靶向AGT的双链siRNA、其缀合物及其用途
Applicants **
SUNSHINE LAKE PHARMA CO., LTD.
Inventors
SHU, Zhiyu
ZOU, Zhifu
XU, Honggui
ZUO, Yinglin
CHEN, Huimeng
LIU, Yayi
WANG, Pu
Priority Data
202411057058.X
02.08.2024
CN
202411680771.X
22.11.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 1886 | |
| EPO | Filing, Examination, Granting | 12593 | |
| Japan | Filing, Examination, Granting | 2212 | |
| South Korea | Filing, Examination, Granting | 2204 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
23,635
Contact Us
Abstract[English]
Provided are an AGT-targeting double-stranded siRNA, a conjugate thereof, and a use thereof. The double-stranded siRNA and the conjugate thereof can inhibit the expression of angiotensinogen (AGT), and can be used for preparing a drug for treating and/or preventing AGT-related diseases.[French]
L'invention porte sur un nouvel ARNsi double brin ciblant AGT, un conjugué associé et une utilisation associée. L'ARNsi double brin et le conjugué associé peuvent inhiber l'expression de l'angiotensinogène (AGT) et peuvent être utilisés pour préparer un médicament pour le traitement et/ou la prévention de maladies associées à l'AGT.[Chinese]
提供了一种靶向AGT的的双链siRNA、其缀合物及其用途，所述双链siRNA及其缀合物可以抑制血管紧张素原(AGT)表达，可制备用于治疗和/或预防AGT相关疾病的药物。